Салтанат Кенбаева

Dr. Салтанат Кенбаева

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2026 in Healthcare
Verified
Journal Article
Open access
PDF file
BABekdaulet Akimniyazova
Bekdaulet Akimniyazova
TYTemur Yeshmuratov
Temur Yeshmuratov
ТМТалгат Алпысбаевич Медетбеков
Талгат Алпысбаевич Медетбеков
ASAxaule Serikbayeva
Axaule Serikbayeva
NANurgulim Akhmad
Nurgulim Akhmad
ATAigul Tazhiyeva
Aigul Tazhiyeva
Background: Echinococcosis, caused by the Echinococcus granulosus, primarily affects the liver and lungs and remains an important public health problem in endemic regions. Surgical treatment remains the main therapeutic approach. Objectives: We aimed to analyze nationwide trends and regional disparities in the treatment and surgical management of echinococcosis in Kazakhstan and to identify factors associated with emergency surgical care. Methods: A retrospective analysis of national healthcare records of treated echinococcosis cases in Kazakhstan from 2017 to 2024 was conducted. The dataset included information on age distribution, hospitalization characteristics, surgical interventions (elective and emergency), and regional patterns. Organ-specific stratification was available in the national database. Descriptive and comparative statistical analyses were performed to evaluate temporal and regional differences. Results: Between 2017 and 2024, the number of treated echinococcosis cases demonstrated a decreasing trend. Significant regional differences in surgical management were identified, with southern regions, particularly Turkistan, showing a higher proportion of emergency surgical interventions (p < 0.05). Forecasting analysis suggested a further decline in treated case numbers; however, widening 95% confidence intervals and the appearance of negative projected values in later years indicated substantial uncertainty and limitations of the predictive model. Conclusions: The decline in treated echinococcosis cases may reflect improvements in disease control, but may also be associated with underdiagnosis or reduced access to healthcare services. Marked regional disparities in emergency surgical care highlight the need to strengthen surveillance systems and improve equitable access to timely diagnosis and treatment.

23 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
BABekdaulet Akimniyazova
Bekdaulet Akimniyazova
TYTemur Yeshmuratov
Temur Yeshmuratov
TMTalgat Medetbekov
Talgat Medetbekov
ASAxaule Serikbayeva
Axaule Serikbayeva
NANurgulim Akhmad
Nurgulim Akhmad
GYGulstan Yessetova
Gulstan Yessetova
Background: Echinococcosis is an infection caused by the Echinococcus Granulosus parasite, mainly affecting the liver and, less commonly, the lungs. Surgical intervention is the main treatment for Echinococcus Granulosus, with various approaches available depending on the cyst characteristics. This study provided a comprehensive assessment of age characteristics, hospitalization length, and regional differences in the surgical treatment of echinococcosis in Kazakhstan. Objectives: To conduct a comparative analysis of regional disparities in surgical management of pulmonary echinococcosis in Kazakhstan and identify organizational factors contributing to the burden of emergency surgeries. Methods: A brief description of the main methods or treatments applied. This can include any relevant preregistration or specimen information. Results: A short summary of the article’s main findings. Conclusions: A final summarizing comment of the main conclusions or interpretations. The abstract should be an objective representation of the article; it must not contain results which are not presented and substantiated in the main text and should not exaggerate the main conclusions. Clinical trial abstracts should include items that the CONSORT group has identified as essential.

20 July 2026 in Genes
Verified
Journal Article
Open access
PDF file
Saken KhaidarovSaken Khaidarov
Saken Khaidarov
AMAizhan Moldakaryzova
Aizhan Moldakaryzova
DDDias Dautov
Dias Dautov
NSNurgul Sagatbayeva
Nurgul Sagatbayeva
BYBanu Yeszhan
Banu Yeszhan
Mukhit KulmaganbetovMukhit Kulmaganbetov
Mukhit Kulmaganbetov
Background: Duchenne muscular dystrophy (DMD) has, for the first time, several mutation-specific drugs in clinical use. Four exon-skipping antisense oligonucleotides and one adeno-associated virus (AAV) micro-dystrophin gene therapy carry US FDA approval, and one nonsense-readthrough agent (ataluren) holds a conditional European authorisation that has since been placed under review; ataluren has never been approved by the FDA. Regulatory approval, however, has not translated cleanly into demonstrable clinical benefit, and in resource-limited settings it has not translated into access at all. Methods: We compiled published efficacy estimates for each approved therapy: the EMBARK randomised trial for delandistrogene moxeparvovec (Elevidys), the STRIDE registry for ataluren, and the long-term extension studies of eteplirsen, golodirsen, viltolarsen and casimersen. We read these alongside mutation-spectrum and clinical data from a Kazakh DMD cohort (n = 34), one of the first Central Asian populations to be characterised systematically. Because these sources differ in design, population, endpoint and follow-up, the comparison is indirect and descriptive rather than pooled or statistical. On that basis we assembled three descriptive maps: biological versus clinical efficacy, eligibility versus access, and an order-of-magnitude estimate of cost per year of preserved ambulation. Results: Across the approved therapies, larger biological dystrophin restoration did not correspond to longer preservation of walking. We describe this as the absence of the expected positive association rather than as evidence of a negative one: the comparison rests on a small number of drugs whose values come from heterogeneous studies. We did not—and with these data could not—test it as a formal correlation. Ataluren, with roughly 2% dystrophin restoration, was associated with a longer reported delay in loss of ambulation than Elevidys, which restores 34–51% micro-dystrophin. In the Kazakh cohort, 26.5% of patients were biologically eligible for exon-skipping and 11.8% for ataluren, yet realistic access to any mutation-specific therapy was effectively zero as of April 2026. Our order-of-magnitude cost estimates ran from about $12,000 per additional year of ambulation for standard of care to about $1.3 million for AAV gene therapy, a hundredfold range that did not track clinical effect. Conclusions: We argue that the conventional priority ordering (gene therapy first, exon-skipping second, standard care as background) does not hold up when weighed against patient-relevant outcomes and cost, and may reasonably be inverted for resource-limited systems. This is our interpretation of an indirect comparison, not an evidence-based clinical recommendation. On that reading, the highest-value investments for Central Asia are early molecular diagnosis, universal access to glucocorticoids and specialised physiotherapy, and individual-import pathways for ataluren, while AAV gene therapy is, in our view, a lower near-term priority until its durability and safety data improve.